Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - SELLAS Life Sciences Group, Inc. | Financial_Report.xls |
| 10-Q - 10-Q - SELLAS Life Sciences Group, Inc. | gale-20140630x10q.htm |
| EX-10.1 - EXHIBIT - SELLAS Life Sciences Group, Inc. | gale-20140630xex101.htm |
| EX-31.1 - EXHIBIT - SELLAS Life Sciences Group, Inc. | gale-20140630xex311.htm |
| EX-31.2 - EXHIBIT - SELLAS Life Sciences Group, Inc. | gale-20140630xex312.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the accompanying Quarterly Report of Galena Biopharma, Inc., (the “Company”) on Form 10-Q for the quarter ended June 30, 2014 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officers of the Company certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to their knowledge:
1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the Company’s financial condition and result of operations.
/s/ Mark Ahn | /s/ Ryan M. Dunlap | |
Mark J. Ahn | Ryan M. Dunlap | |
President and Chief Executive Officer | Vice President, Chief Financial Officer | |
August 11, 2014 | August 11, 2014 | |